<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article14</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PEGASUS-TIMI_54" style="display:block; margin-bottom:10px;">PEGASUS-TIMI 54 Original</a></li>
<h2><strong>PEGASUS-TIMI 54</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ticagrelor in Patients 1 to 3 Years after Myocardial Infarction".<br/>
The New England Journal of Medicine. <br/>
Date Published.<br/>
PMID•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
  6.1 Inclusion Criteria<br/>
  6.2 Exclusion Criteria<br/>
  6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
  8.1 Primary Outcomes<br/>
  8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does long-term use of ticagrelor reduce the risk of cardiovascular events in patients with a history of myocardial infarction?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients 1 to 3 years after a myocardial infarction, long-term ticagrelor at doses of either 90 mg or 60 mg twice daily reduced the risk of cardiovascular death, myocardial infarction, or stroke compared to placebo, but increased the risk of major bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
At the time of the study, guidelines recommended P2Y12 receptor antagonists for up to 1 year post-myocardial infarction. This trial suggests potential modification of these recommendations might be warranted to extend the duration of P2Y12 receptor antagonist therapy in post-myocardial infarction patients.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled, randomized trial<br/>
- N=21,162<br/>
- Randomization to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo<br/>
- Median follow-up: 33 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Patients aged ≥50 with a history of myocardial infarction 1 to 3 years prior<br/>
- Additional risk factors such as age ≥65, diabetes mellitus, another MI, multivessel coronary disease, or chronic renal dysfunction<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Ticagrelor 90 mg twice daily vs. ticagrelor 60 mg twice daily vs. placebo, in addition to low-dose aspirin (75-150 mg daily)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Composite of cardiovascular death, myocardial infarction, or stroke<br/>
- Ticagrelor 90 mg twice daily (7.85%) and 60 mg twice daily (7.77%) each reduced the rate compared to placebo (9.04%)<br/>
Secondary Outcomes<br/>
- TIMI major bleeding was higher with ticagrelor (2.60% with 90 mg, 2.30% with 60 mg) compared to placebo (1.06%)<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- The trial was funded by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text article available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
